Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Tilatamig Samrotecan | AZD9592 » ADC Review
tilatamig samrotecan (AZD9592) / AstraZeneca
阿斯利康的双抗ADC药物在华申请临床获受理（附双抗ADC汇总）_治疗_研究_肿瘤
【AACR 2023】ADC药物”角力”AACR-公司新闻-北京百普赛斯生物科技股份有限公司
A Comprehensive Introduction to Bispecific ADCs | AxisPharm
Phase Ib study of afatinib plus standard-dose cetuximab in patients ...
ADC新药“大闹”AACR 2023年美国癌症研究协会（AACR）年会正在召开，会议涵盖了众多前沿进展、新靶点探索、药物临床突破、新技术和新 ...
Expanding new trends and technologies in ADC therapeutics
AACR2023| ADC药物及可用临床前动物模型 - 知乎
Frontiers | Identifying optimal tumor-associated antigen combinations ...
EGFR敏感突变肺癌新药临床试验：EGFR/c-Met双靶点ADC药物AZD9592-印塔健康官网
The Evolving Paradigm of Antibody–Drug Conjugates Targeting the ErbB ...
靶向EGFR-cMET！阿斯利康ADC新药在中国申报临床
Frontiers | A narrative review of antibody–drug conjugates in EGFR ...
带你了解双抗ADC-MedSci.cn
【AACR 2023】ADC药物”角力”AACR - 自主发布 - 资讯 - 生物在线
Abstract 2961: AZD9592, an EGFR/cMET bispecific antibody-drug conjugate ...
阿斯利康EGFR/c-Met ADC在华申报临床 3月9日，据CDE官网公示， 阿斯利康 ADC药物AZD9592在华申报临床。AZD9592 ...
阿斯利康(AZN.US)三款1类新药在中国获批临床
EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC ...
阿斯利康也“Follow”第一三共
阿斯利康最新财报：只用3天发现173款高质量抗体！肝癌CAR-T疗法的首个临床结果… 今日， 阿斯利康 （AstraZeneca）公司公布了 ...
Abstract 5736: AZD9592: An EGFR-cMET bispecific antibody-drug conjugate ...
双抗ADC全球在研格局 ADC药物在过去十多年间已取得了长足的进展，自2000年第一款药物Mylotarg上市，ADC已历经了三代。截止目前 ...
P1.12-04 In Vivo Efficacy of AZD9592, an EGFR-cMET Bispecific ADC, in a ...
Tilatamig (AZD9592 Antibody) | EGFR/MET抗体 | MCE
Tilatamig (AZD9592 Antibody) | EGFR/MET Antibody | MedChemExpress
Tilatamig samrotecan (AZD9592) | EGFR/c-MET ADC | MedChemExpress
Combination of T cell-redirecting bispecific antibody ERY974 and ...
AZ14170133 (SG 3932) | Drug-Linker Conjugates for ADC | MedChemExpress
阿斯利康双抗（EGFRxcMET)ADC有何启示医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
技术前沿 | 双抗ADC的CMC工艺开发挑战与解决方案 #万物偶联 抗体偶联药物（Antibody-Drug Conjugate, ADC ...
双抗ADC靶点介绍及在研药物研究进展-缔码生物
A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective ...
阿斯利康EGFR/C-Met双靶点ADC——AZD9592专利公开，EGFR端亲和力高低成为重要考量因素医药新闻-ByDrug-一站式医药资源 ...
Clin Cancer Res：AZD9291联合MEK抑制剂克服包含C797S的获得性耐药-MedSci.cn
In vivo antitumor efficacy of AZD9291 in subcutaneous xenograft models ...
Frontiers | Targeting tumor-associated macrophages with STING agonism ...
Strategy to develop an effective EGFR ADC. | Download Scientific Diagram
EGFR下一站：雙抗與ADC
Popular Targets in the Bispecific ADC Pipeline-DIMA BIOTECH
AZ7550, an Active Metabolite of AZD9291 (EGFR TKI), Inhibits the ...
2023AACR | ADC药物一览，多款双抗ADC亮相，恒瑞、石药、Seagen众星云集 2023年第114届美国癌症研究协会年会(AACR ...
How does AstraZeneca's PARP inhibitor differentiate?
(PDF) A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective ...
从EGFR选择性看百利天恒双抗ADC 全球ADC研发热潮，为NSCLC领域贡献出HER3、EGFR、TROP2等诸多优秀的药物靶点，BL ...
EGFR/c-MET双抗一线治疗NSCLC III期研究成功 EGFR/c-MET双抗组合疗法一线线治疗NSCLC III期研究成功2023年 ...
AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR ...
Tilatamig samrotecan(Tilatamig samrotecan) - 药物靶点：EGFR x Top I x c-Met ...
(PDF) Osimertinib (AZD9291), a mutant-selective EGFR inhibitor ...
Antibody-drug Conjugate Information | ADCdb
Bispecific ADCs: A potential game changer for the next generation of ADCs
High efficacy of third generation EGFR inhibitor AZD9291 in a ...
The combination of AZD9291 with a MEK inhibitor effectively inhibits ...
Development of a bispecific antibody targeting PD-L1 and TIGIT with ...
AZD-9592 - Drug Targets, Indications, Patents - Synapse
药明系高管创立，双抗ADC黑马藏不住了_医药_李竞_博士
阿斯利康 B7-H4 ADC 国内临床即将启动！中国研发提速中_药物_Enhertu_研究
(PDF) 456PPRECLINICAL EVIDENCE AND CLINICAL CASES OF AZD9291 ACTIVITY ...
阿斯利康FRα ADC在华申报临床 8月25日，CDE官方显示， 阿斯利康 提交AZD5335的临床试验获得受理。AZD5335 是由FRα ...
强生EGFR/c-MET双抗两项III期成功，隐忧难解，阿斯利康ADC能否逆袭 EGFR/c-MET双抗组合疗法二线治疗NSCLC III期 ...
奥西耐药后的“给力”答案：阿斯利康AZD9592，EGFR/c-MET双靶点ADC，客观缓解率超越70%，开启临床试验招募
(PDF) Acquired Resistance to the Mutant-Selective EGFR Inhibitor ...
【双抗布局】——EGFR / c-MET：大厂必争的肺癌高地 - 知乎
EGFR敏感突变肺癌新药临床试验：EGFR/c-Met双靶点ADC药物AZD9592_研究_治疗_癌细胞
Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of ...
KY-0301(KY-0301) - 药物靶点：EGFR x Tubulin x c-Met_在研适应症：晚期胃癌，结直肠癌，EGFR阳性非 ...
(PDF) Molecular basis for cooperative binding and synergy of ATP-site ...
Synergistic effects of Bcl-2 inhibitors with AZD9291 on overcoming the ...
Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ...
Osimertinib (AZD-9291) | Mutant-Selective EGFR Inhibitor | MedChemExpress
